Matsumura N. PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin can Int J Clin Oncol 2026 Sep 6. doi: 10.1007/s10147-026-03190.
PMID: 42701955